An intriguing pharmacogenomic finding from intervention trials is that only those DM patients with the 2–2 genotype appear to respond to anti-oxidant treatment (vitamin E) with reduced ASCVD risk of up to 50%.100 If these findings are confirmed, then testing for haptoglobin genotype of all DM patients could be recommended, with addition of vitamin E treatment to reduce ASCVD risk for those with the 2–2 genotype. The gene discussed is HP; the disease is diabetes mellitus.